Dose-escalation study to evaluate ORB-011 as single agent, with initial safety, pharmacokinetic and mechanism-based pharmacodynamic readouts. Tony Fadell, inventor of the iPod, co-inventor of the iPhone, founder of Nest, and Principal at Build Collective, joins Orionis Board of Directors. November 15, 2023, BOSTON, MA, and GHENT, Belgium – Orionis Biosciences, a life sciences company pioneering…
News
Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year…
Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer
Boston, MA & Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16…
Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit
Boston, MA and Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today will present preclinical data supporting its Allo-GlueTM protein degradation platform for discovery and rational design of small molecule molecular glues at the 5th Annual Targeted Protein Degradation Summit, taking place…
